Tercica

Tercica is a biopharmaceutical company focused on the development and commercialization of recombinant human insulin-like growth factor-1 for the treatment of short stature and other metabolic disorders. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.